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OBJECTIVES: This study aimed to compare the level of diabetes
knowledge among the residents in Bangkok (the capital) and
other provinces in Central Thailand and investigate factors
affecting diabetes knowledge in both groups. METHODS: A
cross-sectional survey was carried out in ﬁve major areas of
Bangkok and four other Central provinces of Thailand in mid-
2007. Five hundred Thai residents aged greater than or equal
to 15 years in each group were recruited from various public
thoroughfares to complete a structured questionnaire compris-
ing seven sections. RESULTS: The overall diabetes knowledge
scores of most respondents in Bangkok (70.8%) and other prov-
inces (75.4%) were acceptable (deﬁned as greater than or equal
to 50% of the total score). More than half of the respondents had
acceptable scores in every section, except for the section ‘diabetes
in women’. The mean (SD) overall score of the other provinces
group was signiﬁcantly higher than that of the Bangkok group
(60.95  18.95% vs. 58.21  20.69%, p = 0.029). There were
also more respondents with acceptable scores in the other prov-
inces group compared to the Bangkok group in almost every
section. Education level, age, and having family member, relative
or friend with diabetes were important predictors of knowledge
score of respondents in both groups while working status was a
signiﬁcant predictor only in the other provinces group. Friends or
relatives and various kinds of media were reported as major
sources of diabetes information in both groups. CONCLU-
SIONS: The level of diabetes knowledge of respondents in both
groups was satisfactory, except for a few areas. Characteristics
such as education level, age, and having family member, relative
or friend with diabetes were all important in determining level of
diabetes knowledge of the residents in both groups and should
be considered in future planning of public health education
programmes.
PDB66
INSULIN GLARGINE UTILIZATION IN REAL-LIFE—EFFICACY
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OBJECTIVES: This registry evaluated the effectiveness of an
insulin glargine-based regimen in patients with type 2 diabetes
(T2D) in clinical practice settings in Spain. METHODS: Patients
who switched from neutral protamine Hagedorn (NPH) insulin
to glargine at four to nine months prior to inclusion (Study
Group) and patients maintained on NPH 12 months (Control
Group) were included (ratio 2:1) in this cross-sectional, single-
visit registry. Retrospective data from four to nine months prior
to inclusion and current data at a study visit were recorded. The
Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the
change version (DTSQc) were completed by patients in both
groups. RESULTS: Of 1662 patients enrolled, 1482 were
included in this analysis (males/females 690/759): median age 63
(range 19–92) years, BMI 28.5 (17.6–54.9) kg/m2 and diabetes
duration 10.8 (0.5–49.0) years. At the switch, mean  SD HbA1c
was 7.9  1.1 and 8.3  1.2% in the Control and Study Groups,
respectively. At study visit, 506 (34.1%) and 976 (65.9%)
patients were treated with NPH (median dose 36 [8–110] IU) and
glargine (30 [6–100] U), respectively; 65.0% and 73.2% were
taking oral antidiabetic drugs. MeanSD fasting blood glucose
was 157.3  47.5 and 137.8  40.7 mg/dL, (p < 0.0001;
Student’s t test) and HbA1c reduction was 0.2  0.8% (adjusted
mean change: 0.363  0.834%) and 1.0  1.0% (0.874 
0.811%) (p < 0.0001, t test; p < 0.0001, ANCOVA for adjusted
change). 241 (47.6%) and 213 (21.8%) patients reported symp-
tomatic hypoglycaemia in the last month and 42 and 13 patients
had nocturnal hypoglycaemia in the Control and Study Groups,
respectively. Improvements in DTSQc scores were reported in the
Study Group compared with the Control Group (p < 0.0001; t
test). CONCLUSIONS: In this registry in Spain, better glycaemic
control was achieved in T2D patients who were switched from
NPH to glargine-based regimens compared with patients main-
tained on NPH. Glargine is related to less frequent symptomatic
hypoglycaemia and improves treatment satisfaction.
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OBJECTIVES: Recent studies of type 2 diabetes patients suggest
a strong correlation between self-management, satisfaction with
treatment, health outcomes, resource use and costs. However, the
extent to which these factors are applied in diabetes economic
models is unknown. Our study aim was to review the incorpo-
ration of these factors in existing models, and to develop meth-
odological approaches to improve the quality of diabetes
economic models. METHODS: A Cochrane-based systematic
review was conducted among published diabetes economic
models over the past 15 years. Electronic libraries (Medline,
EMBASE) were queried using pre-deﬁned search terms and inclu-
sion criteria. Descriptive statistics were calculated. RESULTS:
Sixteen models were identiﬁed. All utilized biological and clinical
risk equations from large epidemiological studies (e.g., UKPDS,
DCCT) and clinical trials to project disease progression and
future costs. The majority assessed cost-effectiveness, as driven
by: 1) applied clinical beneﬁt (eg, HbA1c reductions) alongside
other characteristics (e.g., gender, age, race/ethnicity), and 2)
treatment-speciﬁc effects and costs for comparative regimen
analysis. Most models were developed fairly recently (n = 11,
69%, after 2002), simulated base-case lifetime scenarios (n = 6;
38%), and were structured for patient transition to speciﬁed
health states (n = 10: 3 decision-analytic, 7 Markov-like). Treat-
ment changes over time were observed in only 25% of models,
and none accounted for heterogeneity in medication adherence,
persistence or satisfaction. CONCLUSIONS: Economic models
in type 2 diabetes contain robust methods for projecting the
biological progression and economic burden of disease based on
clinical parameters. However, the application of important
patient-related factors such as self-management behavior and
treatment preference/satisfaction is lacking. Incorporating the
impact of these factors through structural and mathematical
innovations, namely revising the risk-adjustment of health states
and upper/lower-bound settings for probabilistic simulations, is
likely to increase the validity and precision of modeled outcomes
and costs.
Abstracts A517
